William H. Lewis net worth and biography

William Lewis Biography and Net Worth

Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became chair of the board of directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will serves as the chair of the board of trustees of BioNJ, the life sciences association for New Jersey. Will is a member of the board of trustees of Case Western Reserve University as well as a member of the board of the Helix Acquisition Corp.

What is William H. Lewis' net worth?: The estimated net worth of William H. Lewis is at least $9.26 million as of January 8th, 2024. Mr. Lewis owns 373,538 shares of Insmed stock worth more than $9,263,742 as of April 27th. This net worth estimate does not reflect any other assets that Mr. Lewis may own. Learn More about William H. Lewis' net worth.
How old is William H. Lewis?: Mr. Lewis is currently 50 years old. There are 3 older executives and no younger executives at Insmed. Learn More on William H. Lewis' age.
How do I contact William H. Lewis?: The corporate mailing address for Mr. Lewis and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on William H. Lewis' contact information.
Has William H. Lewis been buying or selling shares of Insmed?: William H. Lewis has not been actively trading shares of Insmed within the last three months. Most recently, William Lewis sold 45,120 shares of the business's stock in a transaction on Monday, January 8th. The shares were sold at an average price of $29.45, for a transaction totalling $1,328,784.00. Following the completion of the sale, the chief executive officer now directly owns 373,538 shares of the company's stock, valued at $11,000,694.10. Learn More on William H. Lewis' trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 271,590 shares worth more than $7,211,082.98. The most recent insider tranaction occured on January, 12th when insider Martina M.D. Flammer sold 4,667 shares worth more than $133,616.21. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 1/12/2024.

William H. Lewis Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/8/2024	Sell	45,120	$29.45	$1,328,784.00	373,538
1/5/2024	Sell	6,979	$29.26	$204,205.54	373,538
10/27/2023	Sell	112,000	$24.08	$2,696,960.00	342,648
1/10/2023	Sell	6,994	$18.00	$125,892.00	265,067
1/5/2023	Sell	7,008	$19.80	$138,758.40	249,708
8/8/2022	Sell	216,800	$27.84	$6,035,712.00	256,716
7/7/2022	Sell	96,614	$23.00	$2,222,122.00	256,716
3/23/2022	Sell	96,614	$23.16	$2,237,580.24
1/11/2022	Sell	2,873	$25.11	$72,141.03
1/5/2022	Sell	7,126	$27.61	$196,748.86
12/27/2021	Sell	46,614	$27.72	$1,292,140.08
12/23/2021	Sell	50,000	$28.21	$1,410,500.00
9/30/2021	Sell	96,614	$27.36	$2,643,359.04
3/16/2021	Sell	50,000	$36.19	$1,809,500.00	229,608
11/4/2020	Sell	200,000	$34.03	$6,806,000.00	129,787
6/25/2019	Sell	400,000	$26.00	$10,400,000.00	480,672
11/1/2018	Buy	15,700	$15.90	$249,630.00	151,247
2/1/2016	Buy	50,000	$13.34	$667,000.00	96,972
11/1/2013	Buy	5,233	$14.28	$74,727.24
7/1/2013	Buy	7,585	$9.83	$74,560.55
4/1/2013	Buy	9,816	$7.58	$74,405.28
1/9/2013	Buy	10,770	$6.90	$74,313.00
12/3/2012	Buy	13,568	$7.36	$99,860.48

William H. Lewis Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $24.80

$24.63

$25.06

50 Day Range

MA: $27.07

$24.11

$29.51

2 Week Range

Now: $24.80

$18.08

$32.00

Volume

1,294,189 shs

Average Volume

2,063,319 shs

Market Capitalization

$3.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

William Lewis Biography and Net Worth

What is William H. Lewis' net worth?

How old is William H. Lewis?

How do I contact William H. Lewis?

Has William H. Lewis been buying or selling shares of Insmed?

Who are Insmed's active insiders?

Are insiders buying or selling shares of Insmed?